ANI Pharmaceuticals
ANIP
68.55
-0.58
-0.84%
ANI Pharmaceuticals
US · ANIP
#2919 by market cap
Listed 1970
68.55
-0.58
-0.84%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Recent news
-
Rating change
Truist Financial Maintains ANI Pharmaceuticals(ANIP.US) With Hold RatingMarket Newswire · 2026/5/11
-
H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $121Market Newswire · 2026/11/6
-
J.P. Morgan Reaffirms Their Buy Rating on ANI Pharmaceuticals (ANIP)TipRanks · 2026/10/22
-
Rating change
Barclays Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/8/26
-
CCORF Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating, Maintains Target Price $90Market Newswire · 2026/11/6
-
Rating change
Leerink Partners Initiates ANI Pharmaceuticals(ANIP.US) With Buy Rating, Announces Target Price $104Market Newswire · 2026/9/9
-
Rating change
Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $115Market Newswire · 2025/11/10
-
Rating change
Truist Financial Downgrades ANI Pharmaceuticals(ANIP.US) to Hold RatingMarket Newswire · 2025/11/10
-
Rating change
CCORF Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating, Maintains Target Price $91Market Newswire · 2026/7/17
-
J.P. Morgan Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $115Market Newswire · 2026/10/22
-
Rating change
Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $115Market Newswire · 2026/1/13
-
Rating change
Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $119Market Newswire · 2026/10/6
-
Rating change
Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $124Market Newswire · 2026/7/14
-
Rating change
Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Cuts Target Price to $119Market Newswire · 2026/8/10
-
Rating change
CCORF Maintains ANI Pharmaceuticals(ANIP.US) With Hold Rating, Cuts Target Price to $90Market Newswire · 2026/8/10
-
Rating change
Piper Sandler Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $111Market Newswire · 2026/4/23
-
Rating change
CCORF Downgrades ANI Pharmaceuticals(ANIP.US) to Hold Rating, Raises Target Price to $91Market Newswire · 2026/7/17
-
Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $121Market Newswire · 2026/11/6
-
Rating change
Jefferies Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $120Market Newswire · 2026/3/25
-
Rating change
Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $124Market Newswire · 2026/1/16
-
H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $121Market Newswire · 2026/9/22
-
Rating change
Guggenheim Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $114Market Newswire · 2025/10/28
-
Rating change
Leerink Partners Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $103Market Newswire · 2025/10/15
-
Rating change
J.P. Morgan Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Maintains Target Price $115Market Newswire · 2026/8/10
-
Rating change
J.P. Morgan Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $115Market Newswire · 2025/9/24
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:01:05 · For reference only, not investment advice and not tailored to your situation.
ANI Pharmaceuticals discussion 0 comments